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SUMMARY Atopic dermatitis (AD) is a common inﬂammatory 
disease involving the skin and frequently other organs 
and systems such as respiratory system. The recently 
recognized atopic nature of the skin inﬂammation in AD 
has raised a growing interest in the treatment with allergen-
speciﬁc immunotherapy (SIT). In this study, the efﬁcacy of 
SIT was evaluated in a group of 37 AD patients aged 5-44 
years: 14 allergic to house dust mites (HDM), 17 to grass 
pollen allergens, and 6 allergic to grass and mugwort 
pollen allergens. IgE-mediated airborne allergy was well 
documented in all cases. SIT was performed with Novo 
Helisen Depot allergy vaccines of appropriate composition. 
Control group included 29 patients with AD and conﬁrmed 
IgE-mediated airborne allergy to analogous allergens: HDM, 
14 patients; grass pollen allergens, 11 patients; and grass 
and mugwort pollen allergens, 4 patients. Conventional 
methods of AD treatment were used in the control group. 
Clinical evaluation of patients was performed with W-AZS 
index after 12, 24, 36 and 48 months of therapy. SIT was 
found to be an efﬁcacious and safe method of treatment for 
selected patients with AD and IgE-mediated airborne allergy. 
The efﬁcacy of this therapeutic method was signiﬁcantly 
higher than that recorded by conventional methods used in 
the control group in all 3 age subgroups and all 3 types of 
airborne allergy (HDM, grass pollen, and grass and mugwort 
pollen). It is concluded that SIT may be a highly promising 
method of controlling skin inﬂammation in AD with the 
potential to prevent the development of AD into respiratory 
allergy.
KEY WORDS: atopic dermatitis; allergy; speciﬁc immuno-
therapy; treatment
INTRODUCTION
 According to the deﬁnition presented at the 
Second International Consensus Conference on 
Atopic Dermatitis (ICCAD II) (1), “atopic derma-
titis (AD) is a pruritic, inﬂammatory, chronic skin 
disease that typically begins in early childhood 
and may continue to recur as adult disease. While 
various patterns of expression may eventually be 
shown to represent different genetic subtypes, 
Acta Dermatovenerol Croat            2006;14(4):230-240                          CLINICAL ARTICLE
231ACTA DERMATOVENEROLOGICA CROATICA
Czarnecka-Operacz and Silny    
Acta Dermatovenerol Croat
Speciﬁc immunotherapy in atopic dermatitis  2006;14(4):
there is no current distinction between adult and 
childhood atopic dermatitis”. The following set of 
consensus statements on AD represent our up-
dated knowledge (2):
• AD is a common chronic inﬂammatory skin 
disease. It is characterized by intense itch-
ing, dry skin, inﬂammation and relapses, and 
it causes physical and emotional distress in 
patients and their families.
• AD is often familial and frequently associated 
with asthma, food allergy, allergic rhinitis, and 
recurrent skin infections.
• Trigger factors such as stress, irritants, mi-
crobes and allergens should be identiﬁed and 
avoided.
• In the absence of cure, early effective treat-
ment should be initiated to reduce the signs, 
symptoms and recurrences, and to prevent 
progression of the disease.
• Emphasis should be put on long-term control 
rather than just reactive management of re-
lapses.
• Topical corticosteroids provide effective, acute 
control but provoke safety concerns when 
used continuously; furthermore, patients do 
not always use steroids as prescribed by their 
physicians.
• There is a need for safe, effective therapy for 
early control and long-term maintenance.
• The new class of topical calcineurin inhibitors 
may fulﬁll this unmet need. 
 Treatment of AD is still a challenge for physi-
cians and in many cases the disease is poorly 
controlled. Topical corticosteroids are responsible 
for various side effects, rebound phenomenon, 
while the lack of conﬁdence in steroid safety also 
adversely affects compliance and undertreatment 
of children with AD. Systemic treatment is associ-
ated with potentially severe adverse effects and 
is generally not recommended except as a last 
resort (3). Phototherapy is inconvenient and may 
carry a risk of future skin cancers or/and photoag-
ing. Immunosuppressants such as cyclosporine 
or azathioprine require appropriate monitoring be-
cause of their potential effects on organ toxicity, in-
creased risk of infections and possibly lymphoma, 
and may interfere with immunization in childhood. 
And ﬁnally allergen-speciﬁc immunotherapy (SIT) 
should be mentioned, because clinical beneﬁt of 
this method has been shown in the treatment of 
AD patients (2). SIT in selected cases of AD pa-
tients with IgE-mediated airborne allergy was one 
of our main interests for the last few years. In our 
opinion SIT fulﬁlls therapeutic objectives for AD 
because it:
• reduces the signs and symptoms of the dis-
ease,
• prevents or reduces recurrences,
• provides long-term management by prevent-
ing exacerbations, and
• modiﬁes the course of the disease.
 This paper presents our results on SIT per-
formed as an open study over a 4-year period, 
and discusses differences recorded in patient 
subgroups divided according to age and type of 
airborne allergy. It is a part of a complex project on 
SIT in AD, which includes a double blind placebo 
controlled 12-month study.
Material and methods
 The study included two groups of AD patients: 
SIT group of 37 patients (25 female and 12 male, 
age range 5-44, mean age 18 years) with moder-
ate to severe disease activity evaluated by W-AZS 
index: 94.5±39.7 points (4,5) (Tables 1 and 2). All 
patients had excoriated skin lesions with intensive 
pruritus. IgE-mediated airborne allergy was con-
ﬁrmed in all patients (clinical evaluation, skin prick 
tests with aeroallergens, total IgE, and IgE against 
aeroallergens); 17 patients were allergic to grass 
pollen allergens, 6 patients to grass and mugwort 
pollen allergens, and 14 patients to house dust 
mite allergens (Dermatophagoides (D.) pteronys-
sinus and Dermatophagoides (D.) farinae). This 
group of patients were administered SIT with 
Novo-Helisen Depot vaccines over a 4-year pe-
riod. Control group consisted of 29 AD patients 
(19 female and 10 male, age range 5-41, mean 
age 17 years) with moderate to severe disease 
activity as assessed by W-AZS index: 86.9±24.0 
points. Before therapy, there was no signiﬁcant 
between group difference in the clinical activity of 
AD. Control group patients met all the criteria for 
SIT but did not want to receive allergy vaccination. 
Eleven of these patients were allergic to grass 
pollen allergens, four to grass and mugwort pol-
len allergens, and 14 to house dust mite allergens 
(D. pteronyssinus and D. farinae). In this group of 
patients conventional methods of treatment were 
used during the 4-year period. 
Speciﬁc immunotherapy
 Novo-Helisen Depot allergy vaccines were used 
in the treatment of the SIT group. The composition 
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of vaccines was selected individually according to 
the clinical and allergological characteristics of pa-
tients. The following allergy vaccines were used:
1. grass pollen allergens 100% in 17 patients
2. grass pollen allergens 80% and mugwort pol-
len allergens 20% in 6 patients
3. house dust mite allergens D. pteronyssinus 
50% and D. farinae 50% in 14 patients
 Novo-Helisen Depot allergy vaccines were 
administered perennially by the classic subcuta-
neous route in all three types of airborne sensi-
tization. The following concentrations of allergen 
extracts were used:
• concentration 1, 50 TE/mL
• concentration 2, 500 TE/mL
• concentration 3, 5000 TE/mL  
(TE=therapeutic unit)
 SIT was performed according to the classic 
protocol, starting with 0.05 mL of concentration 
1 (50 TE/mL). Injections were then administered 
every 7-14 days with gradually increasing doses 
of allergen extracts to the maintenance dose (1 
mL of concentration 3, 5000 TE/mL). Finally, the 
maintenance dose was repeated every 4 weeks 
for the total SIT period of 4 years. The total dose 
administered throughout this period was approxi-
mately 188000 TE (47000TE per year). In case of 
seasonal sensitization during the pollination sea-
son the dose was reduced according to clinical 
picture (by 20%-50% of the planned dose). 
Conventional treatment consisted of antihistamin-
ic drugs (generation I and II), antipruritic agents, 
anti-inﬂammatory agents, topical steroids, mois-
turizing and greasing agents.
 Clinical assessment was performed before and 
after 12, 24, 36 and 48 months of treatment in both 
study groups. W-AZS index was used on clinical 
evaluation of patients (Tables 1 and 2).
Table 1.  W-AZS index
I EVALUATION OF PRURITUS AND LOSS OF SLEEP IN PATIENTS WITH ATOPIC DERMATITIS.
A. PRURITUS EVALUATION:                   
   POINTS 
 No pruritus .............................................................................................................................................       0  
Pruritus is present:
 Extensiveness:
1.  Single or multiple localization of pruritus ................................................................................................  2 
2.  Extensive pruritus involving whole body surface ....................................................................................  6 
 Frequency:
1.  Short episodes of pruritus - less than 30 minutes ..................................................................................   2  
2.  Longlasting pruritus episodes ................................................................................................................  4 
3.  Constant pruritus   .................................................................................................................................  8 
 
 Severity:
1.  Scratching is not necessary  .................................................................................................................  2 
2.  Scratching is necessary  .......................................................................................................................  4 
3.  Anxiety and irritation caused by pruritus ...............................................................................................  8 
 
B. LOSS OF SLEEP EVALUATION:
1.  No loss of sleep  ...................................................................................................................................   0   
2.  Problems in falling asleep  ....................................................................................................................   3 
3.  Night awakening caused by pruritus .....................................................................................................   6  
4.  Sleeplessness  ......................................................................................................................................  12 
                                                                                                        TOTAL  ( A + B )  ......   +   ......  =  I
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Statistical analysis
 Statistical evaluation was performed by use 
of Student’s t-test, ANOVA/MANOVA polydimen-
sional analysis, Wilcoxon test and Mann-Whitney 
U test. For evaluation of correlations, Spearman 
rank correlation coefﬁcient was calculated for sta-
tistical signiﬁcance.
RESULTS
    Clinical efﬁcacy according to age subgroups
 Patients with AD were divided into three age 
subgroups: subgroup 1, children aged 5-14 years 
(n=16); subgroup 2, patients aged 15-21 (n=9); 
and subgroup 3, patients aged >21 (n=12). In the 
control group, the respective ﬁgures were 14, 5 
and 10.
 Mean values of W-AZS score for particular age 
subgroups and statistical analysis of results are 
presented in Tables 3 and 4, and Figure 1. In the 
SIT age subgroup 1, the mean W-AZS score de-
creased from 84.0±39.3 points before treatment to 
5.4±5.2 points after 48-month therapy. At 24, 36 
and 48 months of treatment, the disease severity 
decreased signiﬁcantly (p<0.001) in comparison 
with the initial status. In the SIT age subgroup 2, 
the mean value of W-AZS score was 102.0±38.7 
points before and 21.2±35.3 points after 48 months 
of SIT. A statistically signiﬁcant clinical improve-
ment from the initial status was recorded at 24 
months (p<0.05) as well as at 36 and 48 months 
(p<0.001) of therapy. In the SIT age subgroup 3, 
the mean value of W-AZS score was 102.9±41.1 
points before treatment to decrease to 11.2±10.9 
Table 2. W-AZS index
 II EVALUATION OF EXTENSIVENESS AND SEVERITY OF SKIN  INFLAMMATION
 IN PATIENTS WITH ATOPIC DERMATITIS
  Extensiveness of skin lesions    A   
Severity of skin inﬂammation     
erythema      vesicles         crusts       lichenization    B
edema         erosions        scaling      pigmentation
 
 A x B 
   10        
 1.   Face and neck  
 2.   Scalp and nucha  
 3.   Trunk
       (anterior surface)   
 4.   Trunk         
       (posterior surface)
 5.   Right arm
 6.   Right forearm  
       and hand
 7.   Left arm
 8.   Left forearm
       and hand
 9.   Right thigh
10.  Right shank 
       and foot
11.  Left thigh
12.  Left shank
       and foot
(  )x1=    .....    
(  )x1=    .....
(  )x4=    .....
(  )x4=    .....
(  )x1=    .....
(  )x1=    .....
(  )x1=    .....
(  )x1=    .....
(  )x2=    .....
(  )x2=    .....
(  )x2=    .....
(  )x2=    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....   
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   (  )x3   +      (  )x3      +      (  )x2     +      (  )    =    .....
   .....
   .....
   .....
   .....
   .....
   .....
   .....
   .....
   .....
   .....
   .....
   .....
   .....
                                                                         
                                                                  TOTAL      II
• Score extensiveness of skin lesions 0-3:            •  Score severity of skin inﬂammation 0-3:
         0 = not present    0 = not present
         1 = 1-10% of skin surface involved             1 = mild
         2 = 11-30% of skin surface involved       2 = moderate
         3 = 31-100% of skin surface involved      3 = severe
TOTAL W-AZS : I + II 
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points after treatment. The 24-, 36- and 48-month 
SIT resulted in a signiﬁcant clinical improvement 
(p<0.01 at 24 months, and p<0.001 at 36 and 48 
months). In the control group, patients aged 5-14 
showed a mean pretreatment W-AZS score of 
86.4±28.4 points, which decreased to 42.2±24.0 
points after 48 months. A signiﬁcant improvement 
was recorded at 24, 36 and 48 months of thera-
py (p<0.001, p<0.01 and p<0.001, respectively). 
Patients aged 15-21 treated with conventional 
methods showed a pretreatment W-AZS score of 
99.5±21.2 points, which decreased to 50.6±34.2 
points after 48 months of treatment. A statistically 
signiﬁcant difference in the clinical score in com-
parison with the initial status was only recorded 
at 48 months of treatment (p<0.05). In the control 
subgroup aged >21 the clinical score was as fol-
lows 81.3±17.6 points before and 52.4±23.8 points 
at 48 months of conventional therapy. After 12, 36 
and 48 months of therapy clinical improvement 
was statistically signiﬁcant in comparison with the 
initial status (p<0.01, p<0.001, and p<0.05, re-
spectively). 
 Comparative statistical analysis of clinical re-
sults obtained in the SIT and control groups is pre-
sented in Table 4. In the 5-14 age group there was 
a statistically signiﬁcant difference in favor of SIT 
group after 12, 24, 36 and 48 months of treatment 
(p<0.05 at 12 months, and  p<0.001 at 24, 36 and 
48 months). In the 15-21 age subgroup there was 
a signiﬁcant difference in favor of SIT group af-
ter 24, 36 and 48 months of therapy (p<0.05). In 
the >21 age subgroup a signiﬁcant difference in 
favor of SIT group was recorded after 24,36 and 
48 months of treatment (p<0.01 at 24 months, and 
p<0.001 at 36 and 48 months). 
 Clinical efﬁcacy according to type of 
 air borne allergy
 Tables 5 and 6, and Figure 2 summarize results 
of treatment with allergy vaccines and convention-
al methods in AD patients with different types of 
IgE-mediated airborne allergy. 
 In the SIT group 14 patients were allergic to 
HDM allergens (D. pteronyssinus and D. farinae), 
17 patients were allergic to grass pollen aller-
gens, and 6 patients were allergic to grass and 
mugwort pollen allergens. In patients allergic to 
HDM allergens the mean value of W-AZS score 
was 98.8±44.3 points before and 14.7±25.8 points 
after 48 months of treatment. There was a signiﬁ-
cant difference in the clinical score after 48 months 
of SIT in comparison with the initial clinical status 
of patients (p<0.001). In the group of patients al-
lergic to grass pollen allergens the mean value of 
W-AZS score was 100.1±34.1 points before treat-
ment to decrease to 9.3±15.9 points at 48 months 
of therapy. Results of statistical analysis were sim-
ilar to those recorded in the previous group. A sig-
niﬁcant difference was recorded after 48 months 
of SIT in comparison with the initial clinical score 
(p<0.001). In the group of 10 patients allergic to 
grass and mugwort pollen allergens the mean val-
ue of W-AZS score was 68.6±39.9 points before 
and 7.9±5.9 points after 48 months of SIT, yielding 
a statistically signiﬁcant difference.
 In the control group, there were 14 patients 
allergic to HDM allergens,11 patients allergic to 
grass pollen allergens, and four patients allergic 
to grass and mugwort pollen allergens. In pa-




Figure 1. Mean values of W-AZS score ±SD in the 
SIT and control groups according to age groups 
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of W-AZS score was 80.1±20.2 points before and 
45.3±25.8 points after 4 years of conventional 
treatment. A signiﬁcant improvement of the clini-
cal score in comparison with the initial status was 
recorded at 12 months (p<0.01) and 48 months 
(p<0.001) of therapy. In the 11 patient allergic to 
grass pollen allergens the mean value of W-AZS 
score was 94.6±27.6 points before and 47.8±27.7 
points at 48 months of therapy. After 48 months of 
classic treatment there was a signiﬁcant improve-
Table 3. Mean values of W-AZS score in the SIT and control groups of patients with AD according to age 
groups 
Mean value of W-AZS score (pts)  ±  SD
SIT group Control group
Age (yrs) Age (yrs)












 Before treatment    a 84.0±39.3 102.0±8.7 102.9±41.1 86.4±28.4 99.5±21.2 81.3±17.6
 At 12 months    b 34.8±30.4 35.0±22.4 43.0±36.6 54.2±25.7 65.3±27.7 53.8±16.1
 At 24 months    c 16.1±15.5 15.4±9.9 23.7± 23.9 46.4±26.4 74.9±35.8 52.4±20.8
 At 36 months    d 10.1±7.1 17.6±32.5 12.7±9.8 42.3±19.6 53.5±32.8 45.7±20.5
 At 48 months    e   5.4±5.2 21.2±35.3 11.2±10.9 42.2±24.0 50.6±34.2 52.4±23.8
SIT group:
 age 5-14  a/b; b/c; c/d; d/e (NS)
   a/c; a/d; a/e (p<0.001) 
age 15-21  a/b; b/c; c/d; d/e (NS)
              a/c (p<0.05)
              a/d; a/e (p<0.001)
age >21  a/b; b/c; c/d; d/e (NS)
             a/c (p<0.01)
             a/d; a/e (p<0.001)
Control group:
 age 5-14  a/b; b/c; c/d; d/e (NS)
             a/c (p<0.01)
             a/d; a/e (p<0.001)
 age 15-21  a/b; a/c; a/d; b/c, c/d, d/e (NS)
             a/e (p<0.05)
age >21 a/b (p<0.01)
   a/c; b/c, c/d, d/e (NS)
             a/d (p<0.001)
             a/e (p<0.05)
12
Table 4. Comparative statistical analysis of clinical score (W-AZS) in the SIT and control group
CLINICAL SCORE W-AZS 
  SIT group  Control group 
 Age (yrs)  Age (yrs) 
Statistical

















      a/a p>0.05 
b/b p>0.05 
c/c p>0.05 
 At 12 months
      a/a p<0.05 
b/b p>0.05 
c/c p>0.05 
 At 24 months
      a/a p<0.001 
b/b p<0.05 
c/c p<0.01 
 At 36 months
      a/a p<0.001 
b/b p<0.05 
c/c p<0.001 
 At 48 months
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Table 5. Mean values of W-AZS score ± SD in patients with AD treated with SIT and in control group ac-
cording to type of airborne allergy
 






















 Before treatment      a 98.8± 44.3 100.1±34.1 68.6± 39.9 80.1±20.2 94.6±27.6 89.8±25.0
 At 12 mo                  b 36.8± 32.2 35.0± 28.2 46.4± 35.7 57.1±23.4 58.2±25.1 46.0±14.6
 At 24 mo                 c 18.7±22.7 16.6± 15.1 22.7 ±11.2 53.9±31.3 49.8±26.7 61.1±17.2
 At 36 mo                 d 16.9± 26.0 7.6±6.7 17.5 ±7.3 45.8±25.1 46.2±22.4 41.7±10.4
 At 48 mo                 e 14.7± 25.8 9.3±15.9 7.9 ± 5.9 45.3±25.8 47.8±27.7 51.8±22.5
   
 SIT group
•      patients allergic to HDM allergens
-     a/b; b/c; c/d; d/e (NS)
-     a/e (p<0.001)
• patients allergic to grass pollen allergens
- a/b; b/c; c/d; d/e (NS)
- a/e (p<0.001)
• patients allergic to grass and mugwort pollen 
allergens
- a/b; b/c; c/d; d/e (NS)
- a/e (p<0.001)
 Control group
•  patients allergic to HDM allergens
- a/b (p<0.01)
- a/e (p<0.001)
- b/c; c/d; d/e (NS)
•  patients allergic to grass pollen allergens
-     a/b; b/c; c/d; d/e (NS)
-      a/e (p<0.01)
•  patients allergic to grass and mugwort pollen 
allergens
-      a/b; b/c; c/d; d/e (NS)  
      -       a/e (p<0.05)
Table 6. Results of comparative statistical analysis of the W-AZS clinical score between SIT and control 
groups of patients with AD
16
Table 6. Results of comparative statistical analysis of the W-AZS clinical score between SIT 
and control groups of patients with AD 
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ment of the clinical score in comparison with the 
initial score (p<0.01). In the four patients allergic 
to grass and mugwort pollen allergens treated with 
conventional methods the mean value of W-AZS 
was 89.8±25.0 points before and 51.8±22.5 points 
after 48 months of conventional therapy. In this 
patient subgroup a statistically signiﬁcant differ-
ence was recorded between the initial clinical sta-
tus and the clinical score obtained at 48 months of 
therapy (p<0.05).
 Comparative statistical analysis in the group 
of patients allergic to HDM allergens (Table 6) re-
vealed a statistically signiﬁcant difference of clini-
cal score in favor of SIT patients after 12, 24, 36 
and 48 months of treatment (p<0.05 at 12 months, 
and p<0.01 at 24, 36 and 48 months). In patients 
allergic to grass pollen allergens there was no 
signiﬁcant difference between the SIT and control 
groups before treatment, however, a signiﬁcant 
difference in favor of SIT group was observed at 
12, 24, 36 and 48 months of therapy (p<0.05 at 12 
months, and p<0.01 at 24, 36 and 48 months). In 
patients allergic to grass and mugwort allergens 
there was no signiﬁcant between group difference 
before and after 12 months of therapy, however, 
a signiﬁcant difference in favor of SIT group was 
recorded at 24, 36 and 48 months of treatment 
(p<0.05).
DISCUSSION
 The recent viewpoint on AD immunopathogen-
esis proposes a biphasic cytokine expression as 
a model of disease progression from the early 
acute to the chronic stage of skin inﬂammation. 
It seems that IFNγ/IL-12-dependent TH2→Th1 
switch is responsible for sustained AD progres-
sion, and therefore cytokines themselves might 
be regarded for potential treatment. Controlled 
studies have shown the safety and efﬁcacy of 
long-term use of recombinant IFN-γ (rIFN-γ) in the 
treatment of AD (6-8). Since IFNγ/IL-4 imbalance 
is commonly accepted to be the central immune 
defect in atopic allergy, this therapy seems to be 
very rational and promising. Also considering SIT 
as the only method which is capable of modifying 
the natural course of the atopic process by revers-
ing the imbalance of Th2/Th1 subpopulations, this 
therapy should be considered potentially beneﬁ-
cial. Although scientiﬁc research on SIT has been 
performed for nearly a century (9), its results have 
only recently and partially been accepted (10). 
One of the reasons perhaps lies in the meta-anal-
ysis technique as well as in the scientiﬁc and sta-
tistical methodology used for validation of SIT ef-
ﬁcacy (11,12). The critical difference between the 
symptomatic nature of pharmacological treatment 
and the causal, pathogenic and preventive nature 
of SIT should be clearly stressed. The indications 
for SIT in allergic rhinitis and asthma, only limited 
to cases in which pharmacological treatment is not 
adequate to control symptoms, raise the question 
of the equivalence of therapies (13). Also, discuss-
ing the clinical efﬁcacy of SIT, we base our selec-
tion of studies on the criteria directly extrapolated 
from that of drug trials. DBPC, a randomized study 
design, obviously provides highest grade evidence 




Figure 2. Mean value of W-AZS score ±SD in pa-
tients with AD treated with SIT and in the  control 
group according to type of allergy 
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that exerts its action in a short time and is poorly 
inﬂuenced by confounding factors (13). Clinical re-
sponse in case of SIT is time-related and generally 
a long period is required to limit the inﬂammatory 
process. Therefore, well-designed observational 
studies should also be evaluated for proper analy-
sis of the SIT clinical efﬁcacy, otherwise there is 
a high risk of the result underestimate. The WHO 
position paper states that SIT for AD is only ac-
cepted for clinical trials, as exclusively two DBPC 
trials have been evaluated. According to our 
knowledge, there have been at least 5 such trials 
and results obtained by the authors are promis-
ing (14-18). Therefore, we believe that AD patients 
with IgE-mediated airborne allergy who do not re-
spond to conventional treatment may be selected 
for SIT.
 This paper present results of clinical evaluation 
of SIT performed for 4 years in selected cases of 
AD. We aimed to analyze any possible differences 
according to age and type of airborne allergy. We 
expected SIT to be most effective in youngest AD 
patients with higher adaptive properties of the im-
mune system. In fact, these children presented 
the lowest mean W-AZS score after 48 months of 
SIT; however, the highest score was not recorded 
in the oldest age subgroup but in patients aged 
15-21 (the medium age group). SIT resulted in a 
gradual and continuous clinical improvement in all 
three age subgroups (5-14, 15-21 and >21 years). 
Clinical improvement was recorded already at 12 
months of treatment, but it did not reach statistical 
signiﬁcance (all three subgroups); after 24, 36 and 
48 months it was statistically signiﬁcant. In young-
est patients (age subgroup 1) the clinical score im-
proved more signiﬁcantly after 24 months of SIT in 
comparison with the other two age subgroups and 
it was another age-related difference. In the pa-
tients treated with conventional methods we also 
recorded clinical improvement in all three age sub-
groups. In age subgroup 1 (5-14 years), clinical 
improvement was not signiﬁcant at 12 months, but 
reached statistical signiﬁcance at 24, 36 and 48 
months. In age subgroup 2 (15-21 years) a statisti-
cally signiﬁcant clinical improvement was only re-
corded at 48 months of conventional treatment. In 
age subgroup 3 (>21 years) clinical improvement 
was observed at 12, 36 and 48 months of therapy 
in comparison to the initial score. Therefore, the 
improvement of clinical status in the control group 
was not as steady and continuous as in the SIT 
group.
 Comparative statistical analysis of the SIT and 
control group treatment efﬁcacy revealed signiﬁ-
cant difference in favor of SIT patients in all age 
subpopulations. In the youngest patients this dif-
ference was statistically signiﬁcant after 12, 24, 36 
and 48 months of treatment, and in the other two 
subgroups it was signiﬁcant after 24, 36 and 48 
months of treatment. 
 In conclusion, SIT was more effective than con-
ventional treatment of AD patients in all age sub-
groups, with the best result in youngest patients. 
The children aged 5-14 exhibited better response 
already at 12 months of SIT and the best clinical 
score at the end of the study.
 Another parameter taken into consideration in 
terms of clinical efﬁcacy of SIT was the type of 
IgE-mediated airborne allergy (HDM, grass pol-
len, grass and mugwort pollen). The patients al-
lergic to HDM treated with allergy vaccines (Novo-
Helisen Depot allergy vaccines: D. pteronyssinus 
50%, D. farinae 50%, n=14) showed clinical im-
provement already at 12 months of SIT, however, 
signiﬁcant difference was recorded at 48 months 
of treatment. In the group of patients allergic to 
grass pollen allergens treated with allergy vac-
cines and those allergic to grass and mugwort 
pollen allergens clinical improvement was gradual 
and continuous, and was observed already at 12 
months of SIT, to reach statistical signiﬁcance at 
48 months of treatment. The only exception was 
observed in the group of patients allergic to grass 
pollen allergens during the last year of treatment, 
when their mean W-AZS score slightly increased 
(by 1.7 points). The results obtained in the control 
group were somehow different in all three sub-
populations. In the patients allergic to HDM aller-
gens clinical improvement was signiﬁcant already 
at 12 months of treatment and then at 4 years of 
therapy, although the ﬁnal clinical score in the con-
trol group was much worse in comparison with the 
SIT group (45.3 vs 14.7). The patients allergic to 
grass pollen allergens and those allergic to grass 
and mugwort pollen allergens exhibited signiﬁcant 
clinical improvement only after 48 months of treat-
ment.
 Comparative statistical analysis of the SIT and 
control groups yielded a statistically signiﬁcant dif-
ference in favor of SIT group after 12 months of 
therapy in the patients allergic to HDM and those 
allergic to grass pollen allergens. After 24, 36 and 
48 months of treatment a statistically signiﬁcant 
difference in favor of SIT group was recorded in 
all three allergy type subpopulations (patients al-
lergic to HDM, to grass pollen allergens, and to 
grass and mugwort pollen allergens). It is there-
fore concluded that SIT is more effective than 
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classic treatment of AD irrespective of the type of 
IgE-mediated airborne allergy. However, in case 
of the most complex  type, grass and mugwort pol-
len allergy, a statistically signiﬁcant difference in 
W-AZS score in comparison with the control group 
was observed later than in the other two allergy 
type subpopulations. 
 Allergen speciﬁc immunotherapy has been rec-
ognized by the WHO as the only therapeutic mo-
dality that can affect the natural course of allergic 
diseases (10,19) because of the proven clinical ef-
ﬁcacy and speciﬁc immune changes thus induced. 
At Department of Dermatology and Allergic Dis-
eases Diagnostic Center of the University of Medi-
cal Sciences in Poznań, this method of treatment 
has been carefully studied in AD patients for years 
(20-28). In our opinion, SIT may be an effective 
and promising method of treatment in selected pa-
tients with AD and IgE-mediated airborne allergy. 
This type of systemic therapy is administered to 
correct the immune derangement underlying AD 
and should be considered as one of the elements 
of complex therapeutic strategies in AD.
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